Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | CPB1 | P15086 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.54 |
| ▸ | CASP3 | P42574 | 3/20 | 0.54 |
| ▸ | CTSB | P07858 | 3/20 | 0.52 |
| ▸ | CTSK | P43235 | 3/20 | 0.52 |
| ▸ | CTSS | P25774 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5896898 | 1.00 | ALDH1A1 (0.57) | ALDH1A1GAACPB1TSHREPHX1 | |
| SCHEMBL5897664 | 1.00 | ALDH1A1 (0.57) | ALDH1A1GAACPB1TSHREPHX1 | |
| SCHEMBL2848375 | 1.00 | ALDH1A1 (0.57) | ALDH1A1GAACPB1TSHREPHX1 | |
| SCHEMBL5897658 | 1.00 | ALDH1A1 (0.57) | ALDH1A1GAACPB1TSHREPHX1 | |
| SCHEMBL31064941 | 1.00 | ALDH1A1 (0.57) | ALDH1A1GAACPB1TSHREPHX1 | |
| SCHEMBL18544232 | 0.97 | EPHX1 (0.58) | ALDH1A1GAACPB1TSHREPHX1 | |
| SCHEMBL5749471 | 0.97 | EPHX1 (0.58) | ALDH1A1GAACPB1TSHREPHX1 | |
| SCHEMBL13917140 | 0.97 | EPHX1 (0.58) | ALDH1A1GAACPB1TSHREPHX1 | |
| SCHEMBL13326281 | 0.97 | EPHX1 (0.58) | ALDH1A1GAACPB1TSHREPHX1 | |
| SCHEMBL5751554 | 0.97 | EPHX1 (0.58) | ALDH1A1GAACPB1TSHREPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114650991-A | Bridged ring-fused aldehyde pyridine derivative and application thereof | 北京伯汇生物技术有限公司 | 2022-06-21 | — | — | CN | disclosed |
| CN-112759593-A | Bridged ring-fused aldehyde pyridine derivative and application thereof | 北京伯汇生物技术有限公司 | 2021-05-07 | — | — | CN | disclosed |
| WO-2021067217-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2021-04-08 | — | — | WO | disclosed |
| EP-2685981-B1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL MYERS SQUIBB CO (US) | 2016-08-24 | — | — | EP | disclosed |
| US-7038087-B2 | Process for the production of optically active amino alcohols | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-05-02 | — | — | US | disclosed |
| US-20040063999-A1 | Process for the production of optically active amino alcohols | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1398310-A1 | Process for the production of optically active amino alcohols | Takasago International Corporation (JP) | 2004-03-17 | — | — | EP | disclosed |
| US-5889178-A | N-(2,2-DIPHENYLETHYL)-DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1999-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063999-A1 | Process for the production of optically active amino alcohols | ADH1C, ADH1A, ADH5 | ALDH1A1 22/4885GAA 3298/4885CPB1 2223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.